Picard Medical, Inc. (PMI)
NYSEAMERICAN: PMI · Real-Time Price · USD
0.1658
+0.0099 (6.35%)
Jun 30, 2026, 3:28 PM EDT - Market open
Picard Medical Earnings Call Transcripts
Fiscal Year 2025
-
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 sales expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, positioning the therapy as the new standard of care for adult RRP.
-
Picard Medical, via SynCardia, leads the total artificial heart market with the only FDA-approved device, strong clinical outcomes, and a focus on US and international expansion. Innovation efforts target a fully implantable heart by 2029, with ongoing label expansion and robust patient support.